SK122199A3 - Methods and compositions for modulating responsiveness to corticosteroids - Google Patents
Methods and compositions for modulating responsiveness to corticosteroids Download PDFInfo
- Publication number
- SK122199A3 SK122199A3 SK1221-99A SK122199A SK122199A3 SK 122199 A3 SK122199 A3 SK 122199A3 SK 122199 A SK122199 A SK 122199A SK 122199 A3 SK122199 A3 SK 122199A3
- Authority
- SK
- Slovakia
- Prior art keywords
- corticosteroid
- subject
- oxo
- agent
- modulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
US1634698A | 1998-01-30 | 1998-01-30 | |
PCT/US1998/004916 WO1998041232A2 (fr) | 1997-03-18 | 1998-03-12 | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides |
Publications (1)
Publication Number | Publication Date |
---|---|
SK122199A3 true SK122199A3 (en) | 2000-12-11 |
Family
ID=26688484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1221-99A SK122199A3 (en) | 1997-03-18 | 1998-03-12 | Methods and compositions for modulating responsiveness to corticosteroids |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0998300A1 (fr) |
JP (1) | JP2002504091A (fr) |
KR (1) | KR20000076420A (fr) |
CN (1) | CN1269722A (fr) |
AU (1) | AU734756B2 (fr) |
BG (1) | BG103808A (fr) |
BR (1) | BR9810409A (fr) |
CA (1) | CA2282845A1 (fr) |
DE (1) | DE998300T1 (fr) |
ES (1) | ES2146192T1 (fr) |
HU (1) | HUP0104439A3 (fr) |
ID (1) | ID22975A (fr) |
IL (1) | IL131815A0 (fr) |
NO (1) | NO994506L (fr) |
NZ (1) | NZ337769A (fr) |
PL (1) | PL336464A1 (fr) |
SI (1) | SI20110A (fr) |
SK (1) | SK122199A3 (fr) |
TR (1) | TR199902615T2 (fr) |
WO (1) | WO1998041232A2 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
WO1999022766A2 (fr) * | 1997-10-31 | 1999-05-14 | Terry Strom | Utilisation d'anticorps anti-il12 pour empecher le rejet des greffes |
EP1516630A3 (fr) * | 1997-10-31 | 2006-05-03 | Wyeth | Utilisation d'anticorps anti-il12 pour empêcher le rejet des greffes |
WO1999025737A1 (fr) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions et procedes de traitement de maladies autoimmunes a l'aide d'un anticorps monoclonal se liant a la chaine interleukine-12 beta2 |
EP1076563B1 (fr) * | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptides inhibiteurs de caspase et leur utilisation |
WO2001045747A1 (fr) * | 1998-11-27 | 2001-06-28 | Technion Research & Development Foundation Ltd. | Vaccin base sur un facteur d'induction de l'interferon gamma et utilisation de ce vaccin destine a conferer une immunite de protection contre la sclerose en plaques |
ES2251248T3 (es) * | 1998-12-09 | 2006-04-16 | Protein Design Labs, Inc. | Uso de anticuerpos contra il-12 para tratar la psoriasis. |
AU3876600A (en) | 1999-03-16 | 2000-10-04 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
AU4213500A (en) | 1999-04-09 | 2000-11-14 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
IL131047A0 (en) | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
WO2001016093A1 (fr) | 1999-08-27 | 2001-03-08 | Cytovia, Inc. | ACIDES α-HYDROXY SUBSTITUES INHIBITEURS DE CASPASES ET LEURS UTILISATIONS |
WO2001019373A2 (fr) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
TWI335336B (fr) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
AU2001275228A1 (en) * | 2000-06-06 | 2001-12-17 | Glaxo Group Limited | Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
AU2000270300A1 (en) * | 2000-09-13 | 2002-03-26 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1199074A1 (fr) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Composition pharmaceutique pour la prévention ou le traitement de maladies associées à un excès de production d' IL-12 |
EP1188438A1 (fr) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Compositions pharmaceutiques pour la prévention ou le traitement de maladies associées à un excès de production de l' IL-12 |
KR100857376B1 (ko) * | 2001-01-29 | 2008-09-05 | 라보라토리스 세로노 에스.에이. | 심장 질환의 치료 및/또는 예방에 사용되는 il-18저해물질 |
MXPA03010575A (es) * | 2001-05-16 | 2005-03-07 | Yeda Res & Dev | Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis. |
EP2087908B1 (fr) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Anticorps opgl |
IL161267A0 (en) * | 2001-10-05 | 2004-09-27 | Combinatorx Inc | Combinations for the treatment of immunoinflammatory disorders |
JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
CA2509526A1 (fr) * | 2002-09-24 | 2004-04-15 | Combinatorx, Incorporated | Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires |
WO2004028545A1 (fr) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques |
WO2004067006A1 (fr) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combinaison d'un inhibiteur de la pde iv et d'un antagoniste du tnf-alpha |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
JPWO2005110450A1 (ja) * | 2004-05-17 | 2008-03-21 | 学校法人慶應義塾 | 医薬組成物及び治療方法 |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
US7887802B2 (en) | 2004-07-16 | 2011-02-15 | Atsuo Sekiyama | IL-18 receptor antagonist and pharmaceutical composition containing the antagonist |
WO2006041121A1 (fr) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Traitements prophylactiques ou thérapeutiques de maladie chronique de la peau |
US7829554B2 (en) | 2005-07-14 | 2010-11-09 | Lithera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
MX2009004198A (es) * | 2006-10-17 | 2009-10-19 | Lithera Inc | Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea. |
CA2675233A1 (fr) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Procedes de traitement d'un psoriasis |
EP2527364A1 (fr) | 2007-03-29 | 2012-11-28 | Abbott Laboratories | Anticorps IL-12 anti-humains cristallins |
CN102037011A (zh) | 2008-03-18 | 2011-04-27 | 雅培制药有限公司 | 用于治疗银屑病的方法 |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
KR20140025312A (ko) | 2010-11-24 | 2014-03-04 | 리쎄라 인코오포레이티드 | 지방증 및 윤곽 팽창의 미용적 치료를 위한 선택적인, 친유성, 및 지속성 베타 작용제 단일치료 제형 및 방법 |
WO2015063669A1 (fr) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables |
AU2022353032A1 (en) * | 2021-09-22 | 2024-03-28 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
DK0416950T3 (da) * | 1989-09-08 | 1993-10-11 | Glaxo Group Ltd | Medikamenter |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
HUP9800641A3 (en) * | 1995-04-14 | 2001-04-28 | Glaxo Wellcome Inc Res Triangl | Metered dose inhaler for beclomethasone dipropionate |
-
1998
- 1998-03-12 CA CA002282845A patent/CA2282845A1/fr not_active Abandoned
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/fr not_active Application Discontinuation
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
- 1998-03-12 EP EP98912929A patent/EP0998300A1/fr not_active Withdrawn
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BG103808A (en) | 2000-07-31 |
WO1998041232A3 (fr) | 2000-10-05 |
NO994506D0 (no) | 1999-09-17 |
WO1998041232A2 (fr) | 1998-09-24 |
NZ337769A (en) | 2002-09-27 |
JP2002504091A (ja) | 2002-02-05 |
PL336464A1 (en) | 2000-06-19 |
IL131815A0 (en) | 2001-03-19 |
CA2282845A1 (fr) | 1998-09-24 |
ES2146192T1 (es) | 2000-08-01 |
DE998300T1 (de) | 2001-03-01 |
HUP0104439A3 (en) | 2002-08-28 |
BR9810409A (pt) | 2000-08-22 |
EP0998300A1 (fr) | 2000-05-10 |
TR199902615T2 (xx) | 2000-03-21 |
AU734756B2 (en) | 2001-06-21 |
HUP0104439A2 (hu) | 2002-04-29 |
CN1269722A (zh) | 2000-10-11 |
ID22975A (id) | 1999-12-23 |
AU6760498A (en) | 1998-10-12 |
SI20110A (sl) | 2000-06-30 |
NO994506L (no) | 1999-11-17 |
KR20000076420A (ko) | 2000-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK122199A3 (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
US6054487A (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
WO2001019373A2 (fr) | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides | |
AU735075B2 (en) | Inhibitors of interleukin-1beta converting enzyme | |
JP4748912B2 (ja) | アルキルおよびアリールアラニンp2部分を含むc型肝炎ウイルスに対する大員環ns3−セリンプロテアーゼ阻害剤 | |
US7169760B2 (en) | Peptides as NS3-serine protease inhibitors of hepatitis C virus | |
CA2405521C (fr) | Ns3-serine macrocyclique inhibitrice de la protease du virus de l'hepatite c, comprenant des fragments p2 n cycliques | |
JP4563033B2 (ja) | C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド | |
KR20000064454A (ko) | 인터류킨-1베타전환효소의억제제 | |
AU2006276246A1 (en) | Novel macrocyclic inhibitors of hepatitis C virus replication | |
EP0356223A2 (fr) | Inhibiteurs de HIV-protéase utiles pour le traitement du SIDA | |
JP3112327B2 (ja) | Aceの阻害剤として有用な新規なアミノ及びニトロ含有三環式化合物類 | |
AU2005219859A1 (en) | Inhibitors of hepatitis C virus NS3 protease | |
TW200526687A (en) | Macrocyclic inhibitors of hepatitis C virus NS3 serine protease | |
JPH10501244A (ja) | インターロイキン−1β変換酵素の二環式ラクタム阻害剤 | |
JP2019214574A (ja) | 環状ペプチドおよび医薬としてのその使用 | |
CZ312799A3 (cs) | Přípravky pro modulaci reakce na kortikosteroidy | |
JP2003512450A (ja) | 可溶性ヒトcd23形成阻害剤としてのヒドロキサム酸誘導体 | |
CN116323607A (zh) | 用作alk5抑制剂的萘啶衍生物 | |
MXPA99008433A (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
RU2820150C2 (ru) | Нитрилсодержащие противовирусные соединения | |
RU2786722C1 (ru) | Нитрилсодержащие противовирусные соединения | |
US6613880B2 (en) | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | |
AU2001280637B2 (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | |
ES2344890T3 (es) | Nuevos peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |